EZETIMIBE TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

EZETIMIBE

Beszerezhető a:

SANIS HEALTH INC

ATC-kód:

C10AX09

INN (nemzetközi neve):

EZETIMIBE

Adagolás:

10MG

Gyógyszerészeti forma:

TABLET

Összetétel:

EZETIMIBE 10MG

Az alkalmazás módja:

ORAL

db csomag:

15G/50G

Recept típusa:

Prescription

Terápiás terület:

CHOLESTEROL ABSORPTION INHIBITORS

Termék összefoglaló:

Active ingredient group (AIG) number: 0149164001; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2015-01-07

Termékjellemzők

1
PRODUCT MONOGRAPH
PR
EZETIMIBE
EZETIMIBE TABLETS
10 MG
MANUFACTURER’S STANDARD
Cholesterol Absorption Inhibitor
Sanis Health Inc.
Date of Revision:
1 President’s Choice Circle
January 11, 2022
Brampton, Ontario
L6Y 5S5
Submission Control No.: 259721
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................
4
ADVERSE REACTIONS
..............................................................................................................
7
DRUG INTERACTIONS
............................................................................................................
10
DOSAGE AND ADMINISTRATION
........................................................................................
12
OVERDOSAGE
..........................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
13
STORAGE AND STABILITY
....................................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 15
PART II: SCIENTIFIC INFORMATION
...................................................................................16
PHARMACEUTICAL INFORMATION
....................................................................................
16
CLINICAL TRIALS
.........................................................................................